Curative Biotechnology Company Description
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices.
The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease.
Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor.
The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine.
Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | I. Garr |
Contact Details
Address: 3801 PGA Blvd Palm Beach Gardens, Florida 33410 United States | |
| Phone | 561 907 8990 |
| Website | curativebiotech.com |
Stock Details
| Ticker Symbol | CUBT |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US23128N1081 |
| SIC Code | 6719 |
Key Executives
| Name | Position |
|---|---|
| I. Richard Garr Esq., J.D. | Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and General Counsel |
| Paul M. Michaels | President and Executive Chairman |
| Dr. Ronald Bordens Ph.D. | Executive Vice President of Process Product Drug Development and Member of Scientific and Clinical Advisory Board |